Amy E. Lerman

Jan 21, 2025 | healthlawadvisor.com | Alan Arville |Audrey Davis |Daniel Fahey |Amy E. Lerman

Remote prescribing via telemedicine continues to be a huge area of interest among prescribers and other health care providers. After publishing a Notice of Proposed Rulemaking (“NPRM”) in March 2023 on the prescribing of controlled substances via telemedicine that was widely criticized for being far more restrictive than temporary waivers then in place under the COVID-19 public health emergency, the Drug Enforcement Administration (“DEA”) went back to the drawing board.

Nov 14, 2024 | healthlawadvisor.com | Amy E. Lerman |Audrey Davis

As the dust from the public health emergency (PHE) continues to settle and the PHE-era flexibilities expire, telehealth providers are bracing themselves for the changes soon to come. These providers will inevitably face certain legal and regulatory complexities as federal and state lawmakers and regulators consider adopting further temporary or permanent policy changes impacting telehealth.

Oct 10, 2023 | healthlawadvisor.com | Audrey Davis |Delia Deschaine |Daniel Fahey |Amy E. Lerman

On Friday, October 6, 2023, the Drug Enforcement Administration (“DEA”) and Department of Health and Human Services (“HHS”) filed a Second Temporary Extension of the COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (“Second Temporary Rule”), extending the full set of telemedicine flexibilities adopted during the COVID-19 public health emergency (“PHE”) through December 31, 2024.

Aug 7, 2023 | lexblog.com | Delia Deschaine |Daniel Fahey |Amy E. Lerman

On August 4, 2023, the Drug Enforcement Administration (“DEA”) announced plans to host two public listening sessions, scheduled to take place on September 12 and 13, 2023 at DEA’s headquarters in Arlington, VA, to collect additional input regarding the practice of telemedicine and specifically the remote prescribing of controlled substances without conducting an in-person evaluation of patients before prescribing.

Mar 7, 2023 | lexblog.com | Alan Arville |Delia Deschaine |Amy E. Lerman |Avery Schumacher

On February 24, 2023, the Drug Enforcement Agency (“DEA”) proposed permanent rules around prescribing controlled substances via telemedicine that expand the circumstances under which practitioners can prescribe controlled substances without first conducting an in-person medical evaluation of the patient outside of the COVID-19 public health emergency (“PHE”).